Edgar Filing: DERMA SCIENCES, INC. - Form 25

DERMA SCIENCES, INC. Form 25 May 15, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission	File Number

Derma Sciences, Inc.

NASDAQ OMX BX (formerly, the Boston Stock

Exchange)

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

214 Carnegie Center, Suite 300, Princeton, NJ 08540 609-514-4744 (Address, including zip code, and telephone number, including area code, of Issuer s principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- O CFR 240.12d2-2(a)(1)
- O CFR 240.12d2-2(a)(2)
- O CFR 240.12d2-2(a)(3)
- O CFR 240.12d2-2(a)(4)
- O Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.¹
- X Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Edgar Filing: DERMA SCIENCES, INC. - Form 25

Pursuant to the requirements of the Securities Exchange Act of 1934, Derma Sciences, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

May 15, 2009 By /s/John E. Yetter, CPA Vice President and Chief Financial Officer
Date John E. Yetter, CPA Title

SEC 1654 (03-06)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.